IBRX · Company research
ImmunityBio, Inc. Common Stock (IBRX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| ImmunityBio Falls as Positive ANKTIVA Updates Meet Profit-Taking Pressure - Quiver Quantitative | ImmunityBio Falls as Positive ANKTIVA Updates Meet Profit-Taking Pressure Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 16, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update - Stocktwits | IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update Stocktwits | View source ↗ | Stocktwits | Oct 16, 2026 | neutral | 0 | 0.6 |
| Some bladder cancer patients had complete responses lasting beyond 53 months - Stock Titan | Some bladder cancer patients had complete responses lasting beyond 53 months Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC Win (NASDAQ:IBRX) - Seeking Alpha | ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC Win (NASDAQ:IBRX) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 16, 2026 | neutral | 0 | 0.6 |
| FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer | ImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer | ImmunityBio received FDA approval to expand Anktiva's label for treating BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only disease. The approval, granted three months ahead of schedule, now covers all BCG-unresponsive NMIBC patients. Anktiva sales surged 121% year-over-year to $95 million in the first half of 2026, driven by strong physician adoption and new prescriber demand. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.667 | 1 |
| ImmunityBio Stock Climbs Thursday: What's Going On? - Benzinga | ImmunityBio Stock Climbs Thursday: What's Going On? Benzinga | View source ↗ | Benzinga | Oct 15, 2026 | neutral | 0 | 0.6 |
| Why Are Nasdaq Futures Sinking Premarket? CRWV, MU, TSM, SKHY, IBRX, RKLB, TSLA Stocks In Focus - Stocktwits | Why Are Nasdaq Futures Sinking Premarket? CRWV, MU, TSM, SKHY, IBRX, RKLB, TSLA Stocks In Focus Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| Dow, S&P 500, Nasdaq Decline Amid Hot Inflation Data, AI Selloff: CRWV, NBIS, NVDA, IBRX Stocks In Focus - Yahoo Finance | Dow, S&P 500, Nasdaq Decline Amid Hot Inflation Data, AI Selloff: CRWV, NBIS, NVDA, IBRX Stocks In Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying - Stocktwits | IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying Stocktwits | View source ↗ | Stocktwits | Oct 15, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk - Yahoo Finance | IBRX Stock Eyes Weekly Slump Despite Anktiva FDA Win — Retail Stays Cautious Ahead Of Founder’s Trial Talk Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline - Yahoo Finance | IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals - Yahoo Finance | SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick - Stocktwits | IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Technical Analysis - Pluang | IBRX Stock Technical Analysis Pluang | View source ↗ | Pluang | Oct 11, 2026 | neutral | 0 | 0.6 |
| ImmunityBio Inc. Common Stock (IBRX) Company Profile - Pluang | ImmunityBio Inc. Common Stock (IBRX) Company Profile Pluang | View source ↗ | Pluang | Oct 11, 2026 | neutral | 0 | 0.6 |
| SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology - Stocktwits | SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits | IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement - TradingKey | Immunitybio Inc Stock (IBRX) Moved Up by 8.17% on Oct 9: Drivers Behind the Movement TradingKey | View source ↗ | TradingKey | Oct 9, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Extends Rally As Traders Bet On Oncology Momentum - Timothy Sykes | IBRX Stock Extends Rally As Traders Bet On Oncology Momentum Timothy Sykes | View source ↗ | Timothy Sykes | Oct 9, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Extends Rally As Traders Focus On Oncology Catalysts - StocksToTrade | IBRX Stock Extends Rally As Traders Focus On Oncology Catalysts StocksToTrade | View source ↗ | StocksToTrade | Oct 9, 2026 | neutral | 0 | 0.6 |
| IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - Stocktwits | IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease Stocktwits | View source ↗ | Stocktwits | Oct 9, 2026 | neutral | 0 | 0.6 |
| An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX). - Stock Titan | An officer and director proposes selling 560,000 shares of ImmunityBio (NASDAQ: IBRX). Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months - Yahoo Finance | IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months Yahoo Finance | View source ↗ | Yahoo Finance | Sep 30, 2026 | neutral | 0 | 0.6 |
| ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10% - Yahoo Finance | ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10% Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.